Statistics from Altmetric.com
Given the high disease burden with viral hepatitis, and the advent of highly effective direct-acting antivirals against HCV infection, the WHO is now developing a global strategy to eliminate viral hepatitis by 2030.1 Increasing the uptake of HCV diagnosis and treatment will become a key intervention in achieving this goal.
Although antiviral drugs should be considered for all persons with chronic HCV infection, those with significant liver fibrosis, and especially cirrhosis, should be prioritised for treatment, as they are at increased risk of hepatic complications. Current WHO guidelines for HCV recommend aspartate aminotransferase (AST)-to-platelet ratio index (APRI) or Fib-4 for the fibrosis assessment in low/middle-income countries (LMIC), because of their low cost and wide availability.2 Recently, Lemoine et al 3 developed a novel simple index called γ-glutamyl transpeptidase (GGT) to platelet …
Funding ANRS (12184).
Competing interests None declared.
Ethics approval National Hepatology and Tropical Medicine Research Institute Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.